 BOSTON and ATLANTA , Sept. 8, 2022 PRNewswire -- Inhibikase Therapeutics, Inc. Nasdaq: IKT Inhibikase, a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinsons disease, Parkinsons-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that Milton Werner, Ph.D. 